Impedimed Overview

  • Founded
  • 1999

  • Status
  • Public

  • Employees
  • 73

  • Stock Symbol
  • IPD

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $0.04

  • (As of Thursday Closing)

Impedimed General Information


Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Stock Exchange
Primary Office
  • Unit 1
  • 50 Parker Court
  • Pinkenba, Queensland 4008
  • Australia
+61 (07) 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Impedimed Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.04 $0.04 $0.04 - $0.14 $74.9M 1.78B 1.97M

Impedimed Financials Summary

In Thousands,
TTM 31-Mar-2022 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019
EV 156,626 103,248 29,761 14,578
Revenue 6,227 3,814 2,930
EBITDA (14,117) (13,351) (16,899)
Net Income (15,437) (14,319) (17,248)
Total Assets 25,699 22,719 15,814
Total Debt 356 598 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Impedimed Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Impedimed‘s full profile, request access.

Request a free trial

Impedimed Patents

Impedimed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019348188-A1 Evaluating impedance measurements Pending 27-Sep-2018 0000000000
EP-3856024-A1 Evaluating impedance measurements Pending 27-Sep-2018 0000000000
JP-2020523162-A Index determination Pending 14-Jun-2017 0000000000
EP-3634226-A1 Indicator determination Pending 14-Jun-2017 0000000000
AU-2018286480-A1 Indicator determination Pending 14-Jun-2017 A61B5/0537
To view Impedimed’s complete patent history, request access »

Impedimed Executive Team (5)

Name Title Board Seat Contact Info
Richard Carreon President, Managing Director & Chief Executive Officer
Phil Auckland Chief Financial Officer & Chief Operating Officer
Morten Vigeland Chief Financial Officer
Chris Bulger Director, Business Development
You’re viewing 4 of 5 executive team members. Get the full list »

Impedimed Board Members (2)

Name Representing Role Since
Cherrell Hirst Impedimed Chairman 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Impedimed Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Impedimed Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 26-Oct-2015 0000000000 Surgical Devices 0000000 0
XiTRON Technologies 01-Oct-2007 Merger/Acquisition Electronic Equipment and Instruments 0000000 0
To view Impedimed’s complete acquisitions history, request access »

Impedimed Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 01-Oct-2007 000000000000000000 Completed
  • 000000000
To view Impedimed’s complete exits history, request access »